A lectin mediated delivery system for the intravesical treatment of bladder diseases using poly-(L)-glutamic acid as polymeric backbone

被引:11
作者
Apfelthaler, Christina [1 ]
Gassenbauer, Patrick [1 ]
Weisse, Sandra [1 ]
Gabor, Franz [1 ]
Wirth, Michael [1 ]
机构
[1] Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, Althanstr 14, A-1090 Vienna, Austria
关键词
Intravesical bladder therapy; Lectin; Poly-(L)-glutamic acid; Targeted delivery system; Theranostic; WHEAT-GERM-AGGLUTININ; DRUG-DELIVERY; CANCER CELLS; BINDING; CHEMOTHERAPY; EPIDEMIOLOGY; CYTOINVASION; RECURRENCE; STRATEGY;
D O I
10.1016/j.ejps.2017.10.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, we present a targeted drug delivery system to improve intravesical therapy of bladder diseases. The drug delivery system consists of wheat germ agglutinin (WGA) to facilitate specific interaction with the surface of bladder cells and alpha -poly-W-glutamic acid (PGA) as polymeric backbone to increase the number of drug molecules per targeting moiety. Additionally, fluorescein cadaverine was coupled to PGA to visualise and track the delivery system. Using 5637 single cells and cell monolayers, the optimised F-PGA-WGA delivery system, with an approximate molecular weight of 670 kDa, could convince with its promising cytoadhesive as well as cytoinvasive potential. Using the competitive inhibitor N, N', N"-triacetylchitotriose a specificity of the carbohydrate -mediated interaction between the cell and the delivery system of up to 98% was determined. F-PGA alone did not show any interaction with the cells. Moreover, a high drug loading of 77 molecules of the model drug Dansylcadaverine per backbone was achieved. Microscopic analysis further confirmed binding and uptake of the cytoadhesive polymer even after additional loading with the model drug. Combining the auspicious targeting properties of WGA with the high drug loading possibilities of the backbone might finally lead to an enhanced efficacy when used for intravesical therapy.
引用
收藏
页码:376 / 382
页数:7
相关论文
共 19 条
[1]   Improving efficacy of intravesical chemotherapy [J].
Burgues Gasion, Juan Pablo ;
Jimenez Cruz, Juan Fernando .
EUROPEAN UROLOGY, 2006, 50 (02) :225-234
[2]   Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli [J].
Dhakal, B. K. ;
Kulesus, R. R. ;
Mulvey, M. A. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 :2-11
[3]   Emerging targeted therapies for bladder cancer: a disease waiting for a drug [J].
Dovedi, Simon J. ;
Davies, Barry R. .
CANCER AND METASTASIS REVIEWS, 2009, 28 (3-4) :355-367
[4]   PRECIPITATION AND CARBOHYDRATE-BINDING SPECIFICITY STUDIES ON WHEAT-GERM AGGLUTININ [J].
GOLDSTEIN, IJ ;
HAMMARSTROM, S ;
SUNDBLAD, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1975, 405 (01) :53-61
[5]  
HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ
[6]  
Kaufman Jonathan, 2010, Rev Urol, V12, pe181
[7]   Cell biology and physiology of the uroepithelium [J].
Khandelwal, Puneet ;
Abraham, Soman N. ;
Apodaca, Gerard .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2009, 297 (06) :F1477-F1501
[8]  
Lewis SA, 2000, AM J PHYSIOL-RENAL, V278, pF867
[9]   Poly(L-glutamic acid) - anticancer drug conjugates [J].
Li, C .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :695-713
[10]   Lectin bioconjugates trigger urothelial cytoinvasion - A glycotargeted approach for improved intravesical drug delivery [J].
Neutsch, L. ;
Eggenreich, B. ;
Herwig, E. ;
Marchetti-Deschmann, M. ;
Allmaier, G. ;
Gabor, F. ;
Wirth, M. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 82 (02) :367-375